BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28362666)

  • 1. Dyslipidaemia in type 2 diabetes mellitus: bad for the heart.
    Katsiki N; Tentolouris N; Mikhailidis DP
    Curr Opin Cardiol; 2017 Jul; 32(4):422-429. PubMed ID: 28362666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
    Tuomilehto J
    Diabetes Res Clin Pract; 2003 Jul; 61 Suppl 1():S27-34. PubMed ID: 12880692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes.
    Karalis DG
    Clin Cardiol; 2008 Jun; 31(6):241-8. PubMed ID: 17847038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of dyslipidemia in adults with diabetes.
    Haffner SM
    Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic dyslipidaemia: insights for optimizing patient management.
    Vergès B
    Curr Med Res Opin; 2005; 21 Suppl 1():S29-40. PubMed ID: 15811197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling lipid levels in diabetes.
    Taskinen MR
    Acta Diabetol; 2002 Jun; 39 Suppl 2():S29-34. PubMed ID: 12222625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current management of diabetic dyslipidaemia.
    Betteridge DJ
    Acta Diabetol; 2001; 38 Suppl 1():S15-9. PubMed ID: 11829449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J
    Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Borgia MC; Medici F
    Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of Diabetic Dyslipidaemia.
    Filippatos T; Tsimihodimos V; Pappa E; Elisaf M
    Curr Vasc Pharmacol; 2017; 15(6):566-575. PubMed ID: 28155609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
    Florkowski CM
    Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
    Zhang J; Rocha NA; McCullough PA
    Rev Cardiovasc Med; 2018 Mar; 19(1):13-19. PubMed ID: 31032598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
    Stalenhoef AF; Davidson MH; Robinson JG; Burgess T; Duttlinger-Maddux R; Kallend D; Goldberg AC; Bays H
    Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.